Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol




Brazil; Denosumab; Epidemiology; Giant Cell Tumor of Bone; Margins of Excision; Surgical procedures, Operative.


The giant cell tumor of bone (GCTB) represents approximately 5% of primary bone tumors, and more than half of cases affect individuals between 20 and 50 years of age. Despite being a benign neoplasm, 3 to 5% of cases may show pulmonary metastases, besides it has high potential for bone destruction at the main site of the lesion, often in the epiphyses of long bones, which may lead to serious functional problems in affected patients. Multidisciplinary treatment of GCTB has been a cause for discussion in the last decade due to the discovery of drugs such as denosumab that prevent tumor progression and may be useful in cases of patients with local recurrences and unresectable tumors. The therapeutic basis of GCTB remains the isolated surgical treatment by intralesional (with adjuvants), marginal or wide resection. Intralesional treatment presents higher rates of recurrence, however it preserves the adjacent joint function and much of the individual bone stock. Resection with wide margins presents lower recurrence rates but has shown worse functional results and frequent complications in bone reconstructions. Current knowledge of GCTB surgical outcomes has been based on major world series - there is a lack of Brazilian epidemiological and surgical data on this specific type of neoplasm, except for a few series of cases. The primary objective of this paper is to identify the epidemiological profile of GCTB; the secondary objectives are to describe the surgical aspects in the main diagnostic centers and treatment of bone tumors, to analyze the clinical and surgical aspects of patients with GCTB of wrist and hand, and to analyze the clinical and surgical aspects of patients with knee GCTB. These findings may help in the maintenance or change of national guidelines for the treatment of GCTB. This study protocol was submitted to ethical assessment under the CAAE (Ethical Appreciation Presentation Certificate) registry No. 94280918.0.0000.5327 (5th version), evaluated through the substantiated opinion No. 4.770.705, and approved by the Institutional Research Ethics Committee on June 12, 2022.

Author Biography

Carlos Alberto Souza Macedo, Federal University of Rio Grande do Sul


Balke, M., Ahrens, H., Streitbuerger, A., Koehler, G., Winkelmann, W., Gosheger, G., & Hardes, J. (2009). Treatment options for recurrent giant cell tumors of bone. Journal of cancer research and clinical oncology, 135(1), 149–158.

Baptista, P. P. R., Próspero, J. D., & Yonamine, E. S. (2001). Tumor de células gigantes. Revista brasileira de ortopedia, 36(7), 239–244.

Bertoni, F., Present, D., & Enneking, W. F. (1985). Giant-cell tumor of bone with pulmonary metastases. The Journal of bone and joint surgery. American volume, 67(6), 890–900.

Camargo, O. P., Croci, A. T., Oliveira, C. R. G. C. M., Baptista, A. M., Caiero, M. T., & Giannotti, M. A. (2001). Tumor de células gigantes: evolução histórica do seu diagnóstico e tratamento junto ao Instituto de Ortopedia e Traumatologia da FMUSP. Acta ortopédica brasileira, 9(4), 46–52.

Catalan, J., Fonte A. C., Lusa, J. R. B., Oliveira A. D., Melo, E. S., Justino Júnior, R. O., Min, T. T., Lima, A. C. M., & Gonçalves, C. M. (2006) Tumor de células gigantes ósseo: aspectos clínicos e radiográficos de 115 casos. Radiologia brasileira, 39(2), 119–122.

Deheshi, B. M., Jaffer, S. N., Griffin, A. M., Ferguson, P. C., Bell, R. S., & Wunder, J. S. (2007). Joint salvage for pathologic fracture of giant cell tumor of the lower extremity. Clinical orthopaedics and related research, 459, 96–104.

Eckardt, J. J., & Grogan, T. J. (1986). Giant cell tumor of bone. Clinical orthopaedics and related research,

(204), 45–58.

Ferraz, D. F. C. D., Santos, C. A. T., Costa, V. H. F., Souza, A. M. G., & Lima, P. R. G. (2016). Tumor de células gigantes: Análise sobre importância do diagnóstico precoce e perfil epidemiológico. Revista brasileira de ortopedia, 51(1), 58–62.

Lackman, R. D., Crawford, E. A., King, J. J., & Ogilvie, C. M. (2009). Conservative treatment of Campanacci grade III proximal humerus giant cell tumors. Clinical orthopaedics and related research, 467(5), 1355–1359.

Luengo-Alonso, G., Mellado-Romero, M., Shemesh, S., Ramos-Pascua, L., & Pretell-Mazzini, J. (2019). Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Archives of orthopaedic and trauma surgery, 139(10), 1339–1349.

O'Donnell, R. J., Springfield, D. S., Motwani, H. K., Ready, J. E., Gebhardt, M. C., & Mankin, H. J. (1994). Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. The Journal of bone and joint surgery. American volume, 76(12), 1827–1833.

Prosser, G. H., Baloch, K. G., Tillman, R. M., Carter, S. R., & Grimer, R. J. (2005). Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clinical orthopaedics and related research, (435), 211–218.

Rigollino, A. V., Fernando, T. S., Tanaka, M. H., & Souza, M. M. (2017). Tumor de células gigantes localmente avançado ao nível do joelho: tratamento e revisão da literatura. Revista brasileira de ortopedia, 52(4), 473–478.

Siebenrock, K. A., Unni, K. K., & Rock, M. G. (1998). Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. The Journal of bone and joint surgery. British volume, 80(1), 43–47.

Turcotte R. E. (2006). Giant cell tumor of bone. The Orthopedic clinics of North America, 37(1), 35–51.




How to Cite

BECKER, R. G. .; PEREIRA, B. A. .; GALIA, C. R. .; CADORE, O. P. .; FÜHR, B. .; PESTILHO, J. F. C. S.; MACEDO, C. A. S. .; RABUSXKE, W. B. S. .; RODRIGUES, E. da S.; GUEDES, A. Giant cell tumor of bone: Epidemiological profile (fifth version) – A study protocol. Research, Society and Development, [S. l.], v. 11, n. 10, 2022. DOI: 10.33448/rsd-v11i10.33230. Disponível em: Acesso em: 30 nov. 2022.



Note Preview